Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478088 | 1.00 | EPHX2 (0.44) | EPHX2CYP2C9NAAAMAPTGRIN1 | |
| SCHEMBL21842101 | 0.82 | EPHX2 (0.47) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL21525523 | 0.82 | EPHX2 (0.47) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL17869601 | 0.82 | EPHX2 (0.47) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL17869600 | 0.82 | EPHX2 (0.47) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL21547716 | 0.82 | KDM4E (0.56) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL17869155 | 0.82 | KDM4E (0.56) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL17869153 | 0.82 | KDM4E (0.56) | EPHX2CYP2C9NAAAGRIN1GRIN2B | |
| SCHEMBL25225702 | 0.82 | GPR119 (0.41) | SMN1; SMN2ABL1 | |
| SCHEMBL30420794 | 0.82 | GPR119 (0.41) | SMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185570-B1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-10-09 | — | — | EP | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194441-A | Cyclohexyl-substituted triazoles as vasopressin receptor V1A antagonists | 豪夫迈·罗氏有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-2760871-B1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-8828989-B2 | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2760871-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-2370441-B1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-8461152-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013045373-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | SCHNIDER PATRICK (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8227458-B2 | Arylcyclohexylethers of dihydrotetraazabenzoazulenes | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2370441-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | HOFFMANN-LA ROCHE, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | EPHX2 4328/4885CYP2C9 1788/4885NAAA 3646/4885 |
| US-20130079333-A1 | OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS | AVPR1A, AVPR1B, ADRA2A | EPHX2 2119/4885CYP2C9 511/4885NAAA 2829/4885 |
| US-20120225865-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | EPHX2 3294/4885CYP2C9 288/4885NAAA 3269/4885 |
| US-20100137286-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES | AVPR1A, AVPR1B, AVPR2 | EPHX2 3294/4885CYP2C9 288/4885NAAA 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.